Amikacin Pharmacokinetics in Adults: a Variability That Question the Dose Calculation Based on Weight.

被引：8

作者：

Bourguignon, Laurent ^{[1
,2
,3
]}

Goutelle, Sylvain ^{[1
,2
,3
]}

Gerard, Cecile ^{[2
]}

Guillermet, Anne ^{[2
]}

de Saint Martin, Julie Burdin ^{[2
]}

Maire, Pascal ^{[1
,2
,3
]}

Ducher, Michel ^{[1
,2
]}

机构：

[1] Hop Antoine Charial, Hosp Civils Lyon, Serv Pharm, F-69340 Francheville, France

[2] Hop Antoine Charial, ADCAPT, Serv Pharm, F-69340 Francheville, France

[3] Univ Lyon 1, Ecole Doctorale E2M2 Evolut Ecosyst Microbiol Mod, F-69622 Villeurbanne, France

来源：

THERAPIE | 2009年 / 64卷 / 01期

关键词：

amikacin; drug dosage calculations; pharmacokinetics; POPULATION PHARMACOKINETICS; CREATININE CLEARANCE; PERFORMANCE;

D O I：

10.2515/therapie/2009009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Amikacin Pharmacokinetics in Adults: a Variability That Question the Dose Calculation Based on Weight. The use of amikacin is difficult because of its toxicity and its pharmacokinetic variability. This variability is almost ignored in adult standard dosage regimens since only the weight is used in the dose calculation. Our objective is to test if the pharmacokinetic of amikacin can be regarded as homogenous, and if the method for calculating the dose according to patients' weight is appropriate. From a cohort of 580 patients, five groups of patients were created by statistical data partitioning. A population pharmacokinetic analysis was performed in each group. The adult population is not homogeneous in term of pharmacokinetics. The doses required to achieve a maximum concentration of 60 mg/L are strongly different ( 585 to 1507 mg) between groups. The exclusive use of the weight to calculate the dose of amikacine appears inappropriate for 80% of the patients, showing the limits of the formulae for calculating doses of aminoglycosides.

引用

页码：47 / 53

页数：7

共 24 条

[1] NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].

AKAIKE, H .

IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723

[2]

[Anonymous], 1986, HDB BASIC PHARMACOKI

[3] AMIKACIN PHARMACOKINETICS IN MORBIDLY OBESE PATIENTS [J].

BAUER, LA ;

BLOUIN, RA ;

GRIFFEN, WO ;

RECORD, KE ;

BELL, RM .

AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1980, 37 (04) :519-522

[4]

Belfayol Laurence, 1996, Clin Microbiol Infect, V2, P186

[5] Pharmacokinetic and pharmacodynamic bases of empirical antibiotic therapy [J].

Bourgoin, A ;

Martin, C .

ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2004, 23 (06) :626-630

[6] Population pharmacokinetics of amikacin in critically ill patients [J].

Bressolle, F ;

Gouby, A ;

Martinez, JM ;

Joubert, P ;

Saissi, G ;

Guillaud, R ;

Gomeni, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) :1682-1689

[7] Parametric and nonparametric population methods - Their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies [J].

Bustad, A ;

Terziivanov, D ;

Leary, R ;

Port, R ;

Schumitzky, A ;

Jelliffe, R .

CLINICAL PHARMACOKINETICS, 2006, 45 (04) :365-383

[8] A formula to estimate the approximate surface area if height and weight be known [J].

Du Bois, D ;

Du Bois, EF .

ARCHIVES OF INTERNAL MEDICINE, 1916, 17 (06) :863-871

[9] Renal elimination of amikacin and the aging process [J].

Ducher, M ;

Maire, P ;

Cerutti, C ;

Bourhis, Y ;

Foltz, F ;

Sorensen, P ;

Jelliffe, R ;

Fauvel, JP .

CLINICAL PHARMACOKINETICS, 2001, 40 (12) :947-953

[10]

Evans WilliamE., 1992, APPL PHARMACOKINETIC

← 1 2 3 →